Achievements in colorectal cancer care during 8 years of auditing in The Netherlands
Michael P.M. de Neree tot Babberich(Amsterdam University Medical Centers), Th. Wiggers, Djamila Boerma(St. Antonius Ziekenhuis), Marloes A.G. Elferink(Netherlands Comprehensive Cancer Organisation), Hans Gelderblom(Leiden University Medical Center), J. Han van Krieken(Radboud University Nijmegen), Rob A.�E.�M. Tollenaar(Leiden University Medical Center), Evelien Dekker(Academic Medical Center), T.M. Karsten, V.E.P.P. Lemmens(Erasmus MC), Irıs D. Nagtegaal(Radboud University Nijmegen), P.P. Coenen, Willem A. Bemelman(Vrije Universiteit Amsterdam), Jan Willem T. Dekker(Reinier de Graaf Hospital), Michel W.J.M. Wouters(The Netherlands Cancer Institute), Robin Detering(University of Amsterdam), E.H. Eddes(Deventer Ziekenhuis), Pieter J. Tanis(Erasmus MC), Eric R. Manusama, Nicoline J. van Leersum(Leiden University Medical Center), W. J. H. J. Meijerink(Radboud University Nijmegen), Regina G. H. Beets‐Tan(Maastricht University), Corrie A.M. Marijnen(Leiden University Medical Center), C J van de Velde(Leiden University Medical Center), E. van der Harst
Cited by 64
Related Papers
Colorectal cancer
|The Lancet|2019|5k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k